A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin

被引：0
|
作者：
Michal Witkowski
Lars Wilkinson
Neil Webb
Alan Weids
Divina Glah
Hrvoje Vrazic
机构：
[1] DRG Abacus,
[2] Novo Nordisk A/S,undefined
[3] Novo Nordisk Ltd.,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Basal insulin; GLP-1 receptor agonist; Glycemic control; HbA; Network meta-analysis; Semaglutide; Systematic review; Systolic blood pressure; Type 2 diabetes; Weight;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1233 / 1251
页数：18
相关论文
共 50 条
  • [1] A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
    Witkowski, Michal
    Wilkinson, Lars
    Webb, Neil
    Weids, Alan
    Glah, Divina
    Vrazic, Hrvoje
    DIABETES THERAPY, 2018, 9 (03) : 1233 - 1251
  • [2] A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
    Webb, Neil
    Orme, Michelle
    Witkowski, Michal
    Nakanishi, Rie
    Langer, Jakob
    DIABETES THERAPY, 2018, 9 (03) : 973 - 986
  • [3] A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
    Neil Webb
    Michelle Orme
    Michal Witkowski
    Rie Nakanishi
    Jakob Langer
    Diabetes Therapy, 2018, 9 : 973 - 986
  • [4] A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
    Michal Witkowski
    Lars Wilkinson
    Neil Webb
    Alan Weids
    Divina Glah
    Hrvoje Vrazic
    Diabetes Therapy, 2018, 9 : 1149 - 1167
  • [5] A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs
    Witkowski, Michal
    Wilkinson, Lars
    Webb, Neil
    Weids, Alan
    Glah, Divina
    Vrazic, Hrvoje
    DIABETES THERAPY, 2018, 9 (03) : 1149 - 1167
  • [6] The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review
    Ruan, Zhen
    Yang, Lisong
    Shi, Honghao
    Yue, Xiaomeng
    Wang, Yao
    Liang, Miaoying
    Hu, Hao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 221 - 233
  • [7] A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Kayaniyil, Sheena
    Lozano-Ortega, Greta
    Bennett, Heather A.
    Johnsson, Kristina
    Shaunik, Alka
    Grandy, Susan
    Kartman, Bernt
    DIABETES THERAPY, 2016, 7 (01) : 27 - 43
  • [8] A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Sheena Kayaniyil
    Greta Lozano-Ortega
    Heather A. Bennett
    Kristina Johnsson
    Alka Shaunik
    Susan Grandy
    Bernt Kartman
    Diabetes Therapy, 2016, 7 : 27 - 43
  • [9] A network meta-analysis to compare once weekly dulaglutide versus other GLP-1 receptor agonists in patients with type 2 diabetes
    Padhiar, A.
    Thompson, J. C.
    Eaton, J. N.
    Hawkins, N. S.
    Norrbacka, K.
    Reaney, M.
    Shaginian, R.
    Boye, K. S.
    Varol, N.
    DIABETOLOGIA, 2014, 57 : S340 - S341
  • [10] Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes
    Trujillo, Jennifer
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 : 43 - 60
12345